|Ms. Melanie Jaye Leydin B.Bus (Acc/Law), CA||Chief Financial Officer and Company Sec.||54.5k||N/A||44|
Alchemia Limited, a biopharmaceutical company, engages in developing oncology products. It provides Fondaparinux sodium, a generic anti-coagulant drug. The company also offers HyACT, a platform technology that targets cancer drugs directly to tumours, designed to increase effectiveness against tumours without increasing toxicity. In addition, its lead product candidate is HA-Irinotecan, an off-patent chemotherapy drug, which is used in the treatment of metastatic colorectal cancer. The company develops HA-Doxorubicin that has completed a Phase I/IIa clinical trial in patients with metastatic cancers; monoclonal antibodies; and anticancer compounds through active transport to cancer cells through the CD44 receptor. Alchemia Limited was founded in 1995 and is headquartered in South Melbourne, Australia.
Alchemia Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.